LONDON – Novartis AG is looking to the commercialization of its CAR T-cell cancer immunotherapies in a $104 million-plus royalties manufacturing deal with Oxford Biomedica plc, to use the gene therapy specialist's Lentivector technology to transfect patients' T cells.